Profile data is unavailable for this security.
About the company
Fine Foods & Pharmaceuticals NTM SpA, formerly Innova Italy 1 SpA, is an Italy-based pharmaceutical company. It is specialized in the manufacturing of pharmaceutical products for third parties. The Company manages three segments: Pharmaceuticals, Nutraceuticals and Medical Devices. The Pharmaceuticals segment includes powders and granules, tablets, coated tablets and hard gelatin capsules, packaged in sachets, blisters and bottles. The Nutraceuticals segment includes soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, coated tablets and hard gelatin capsules packaged in bags, sachets, sticks, jars, tablet bottles, blisters and strips. The Medical Devices segment includes tablets, capsules, powders, granules and cover the areas for gastrointestinal, oral and throat treatment and the weight management. Medical Devices marked CE (European Conformity) are available for licensing.
- Revenue in EUR (TTM)251.81m
- Net income in EUR-3.52m
- Incorporated--
- Employees753.00
- LocationFine Foods & Pharmaceuticals NTM SpAVia Berlino, 39, ZingoniaVERDELLINO 24040ItalyITA
- Websitehttps://www.finefoods.it
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avacta Group Plc | 18.83m | -49.45m | 172.97m | 120.00 | -- | 4.96 | -- | 9.19 | -0.1605 | -0.1633 | 0.0606 | 0.0826 | 0.2406 | 4.50 | 2.38 | 133,541.70 | -63.18 | -- | -119.23 | -- | 54.40 | -- | -262.60 | -- | 0.6603 | -1.66 | 0.6913 | -- | 228.22 | -- | -49.92 | -- | -- | -- |
| Vicore Pharma Holding AB | 8.97m | -18.32m | 174.01m | 26.00 | -- | 4.14 | -- | 19.40 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 181.33m | 62.00 | -- | 7.82 | -- | 81.42 | -1.18 | -1.18 | 0.1166 | 1.06 | 0.0256 | -- | 3.22 | -- | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -97.81 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Allergy Therapeutics plc | 62.58m | -59.00m | 184.82m | 635.00 | -- | 5.94 | -- | 2.95 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Newron Pharmaceuticals SpA | 9.05m | -16.22m | 187.01m | 23.00 | -- | -- | -- | 20.66 | -0.9008 | -0.9008 | 0.5029 | -1.66 | 0.2873 | -- | 4.57 | 390,147.90 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
| Cellectis SA | 8.50m | -101.15m | 187.12m | 235.00 | -- | 2.39 | -- | 22.03 | -1.73 | -1.62 | 0.1537 | 1.09 | 0.0309 | -- | 13.71 | 36,151.18 | -39.24 | -24.08 | -60.81 | -30.69 | -- | -64.64 | -1,270.92 | -308.24 | -- | -5.08 | 0.5429 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
| Xlife Sciences AG | 997.25k | 15.01m | 191.04m | 17.00 | 27.26 | 0.6923 | 7.48 | 191.56 | 1.22 | 1.22 | 0.1382 | 47.95 | 0.002 | -- | 0.2044 | 58,143.53 | 1.85 | -- | 2.33 | -- | 45.43 | -- | 938.17 | -- | -- | -- | 0.1345 | -- | -3.85 | -- | 3.96 | -- | -- | -- |
| Fine Foods & Pharmaceuticals NTM SpA | 251.81m | -3.52m | 194.13m | 753.00 | -- | 1.70 | 15.40 | 0.7709 | -0.1678 | -0.1678 | 11.51 | 5.18 | 0.9303 | 4.42 | 6.51 | 334,411.40 | -1.30 | -0.3116 | -1.98 | -0.4418 | 27.32 | 27.88 | -1.40 | -0.3935 | 0.6802 | 2.34 | 0.3434 | -- | 21.73 | 12.56 | 62.93 | -- | -26.87 | 3.71 |
| Genovis AB | 10.93m | 2.64m | 198.58m | 36.00 | 75.22 | 11.25 | 55.68 | 18.17 | 0.4686 | 0.4686 | 1.94 | 3.13 | 0.5084 | -- | -- | 3,432,784.00 | 12.28 | 18.56 | 13.37 | 21.45 | 66.09 | 65.51 | 24.15 | 23.88 | -- | -- | 0.2769 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
| Celon Pharma SA | 50.73m | -6.59m | 199.72m | 513.00 | -- | 1.91 | 30.44 | 3.94 | -0.5508 | -0.5508 | 4.24 | 8.73 | 0.3574 | 2.08 | 7.23 | -- | -4.64 | -2.24 | -5.57 | -2.57 | 68.92 | 70.71 | -12.99 | -7.79 | 1.89 | -- | 0.0543 | -- | 11.29 | 11.57 | 28.40 | -- | -13.42 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -30.94m | 200.63m | 34.00 | -- | -- | -- | -- | -0.4038 | -0.4038 | 0.00 | -0.1876 | 0.00 | -- | -- | 0.00 | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Probi AB | 52.28m | -51.80k | 201.98m | 167.00 | -- | 1.65 | 24.46 | 3.86 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Egetis Therapeutics AB (publ) | 5.40m | -28.13m | 203.93m | 30.00 | -- | 5.01 | -- | 37.74 | -1.22 | -1.22 | 0.2326 | 1.62 | 0.0913 | 28.00 | 4.33 | 2,325,926.00 | -47.48 | -33.02 | -53.33 | -36.46 | 82.17 | -- | -520.22 | -357.72 | 2.53 | -144.77 | 0.2014 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Genfit SA | 38.18m | -28.89m | 206.93m | 159.00 | -- | 3.04 | -- | 5.42 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| hVIVO PLC | 65.85m | 18.94m | 208.65m | 274.00 | 11.16 | 5.17 | 9.43 | 3.17 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| 4Basebio PLC | 415.95k | -7.37m | 211.40m | -- | -- | 50.74 | -- | 508.23 | -0.5094 | -0.5094 | 0.0287 | 0.2769 | 0.0296 | 0.3977 | 4.88 | -- | -52.42 | -- | -60.21 | -- | 80.51 | -- | -1,772.60 | -- | 3.28 | -40.29 | 0.6683 | -- | -20.71 | -- | -59.20 | -- | -- | -- |
Data as of May 22 2024. Currency figures normalised to Fine Foods & Pharmaceuticals NTM SpA's reporting currency: Euro EUR
10.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2023 | 607.01k | 2.75% |
| AcomeA SGR SpAas of 30 Jun 2023 | 440.18k | 2.00% |
| Amundi SGR SpAas of 29 Feb 2024 | 380.00k | 1.72% |
| Azimut Capital Management SGR SpAas of 30 Apr 2024 | 228.15k | 1.03% |
| Lupus alpha Asset Management AGas of 30 Jun 2023 | 220.00k | 1.00% |
| Kairos Partners SGR SpAas of 30 Jun 2023 | 176.31k | 0.80% |
| Mediolanum Gestione Fondi SGRpAas of 29 Dec 2023 | 170.95k | 0.78% |
| Fideuram Asset Management SGR SpAas of 29 Apr 2024 | 66.66k | 0.30% |
| Mandarine Gestion SAas of 29 Feb 2024 | 65.00k | 0.30% |
| Banor SIM SpAas of 31 Mar 2024 | 48.33k | 0.22% |
More ▼
Data from 02 Nov 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
